Strategies for Global Prevention of Hepatitis B Virus Infection

  • Pierre Van Damme
  • Alessandro R. Zanetti
  • Daniel Shouval
  • Koen Van Herck
Chapter
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 659)

Abstract

HBV is a double-stranded, enveloped virus of the Hepadnaviridae family. The Hepadna virus family has the smallest genome of all replication competent animal DNA viruses. The single most important member of the family is HBV. Eight genotypes of HBV have been identified; they have been termed A-H. These genotypes are associated with a particular geographic distribution: genotype A being most common in the United States and Northern Europe, B and C in Asia, and D in Mediterranean countries and the Middle East (Table ). he association of HBV genotypes with different clinical outcome and response to interferon has been described: chronic infection with genotype B appears to have a better prognosis than genotype C. Pre-core mutant infection is also most common in genotypes B, C and D, which explains why pre-core mutant infection is more common in Asia and Southern Europe. Further research is currently being performed on the role of these genotypes in transmission, disease pattern, and response to therapy

References

  1. Banatvala, J.E., & Van Damme, P. (2003). Hepatitis B vaccine-do we need boosters? J Hepatol, (10), 1–6.Google Scholar
  2. Banatvala, J.E., Van Damme, P., & Emiroglu, N. (2006). Hepatitis B immunization in Britain: time to change? BMJ, (332), 804–805.PubMedCrossRefGoogle Scholar
  3. Bonanni, P., Pesavento, G., Bechini, A., Tiscione, E., Mannelli, F., Benucci, C., & Nostro, A.L. (2003). Impact of universal vaccination programmes on the epidemiology of hepatitis B: 10 years of experience in Italy. Vaccine, (21), 685–691.PubMedCrossRefGoogle Scholar
  4. Centers for Disease Control and Prevention 1987 (1987). Recommendations of the immunization practices advisory committee. Update on hepatitis B prevention. Morbid Mortal Weekly Report, (36), 353–360.Google Scholar
  5. Chan, C.Y., Lee, S.D., & Lo, K.J. (2004). Legend of hepatitis B vaccination: the Taiwanese experience. J Gastroenterol Hepatol, (19), 121–126.PubMedCrossRefGoogle Scholar
  6. Chen, C.-J., Yang, H.-I., Su, J., Jen, C.-L., You, S.-L., Lu, S.-N., Huang, G.-T. et al. (2006). Risk of HCC across a biological gradient of serum HBV-DNA levels. JAMA, (295), 65–73.PubMedCrossRefGoogle Scholar
  7. Coursaget, P., Leboulleux, D., Soumare, M., le Cann, P., Yvonnet, B., Chiron, J.P. et al. (1994). Twelve-year follow-up study of hepatitis B immunisation of Senegalese infants. J Hepatol, (21), 250–254.PubMedCrossRefGoogle Scholar
  8. Da Villa, G., Romanò, L., Sepe, A., Iorio, R., Parimbello, N., Zappa, A., & Zanetti, A.R. (2007). Impact of hepatitis B vaccination in high endemic area of south Italy and long-term duration of anti-HBs antibody in two cohort of vaccinated individuals. Vaccine, (25), 3133–3136.PubMedCrossRefGoogle Scholar
  9. Dienstag, J.L., Werner, B.G., Polk, B.F., Snydman, D.R., Craven, D.E., & Platt, R. (1984). Hepatitis B vaccine in health care personnel: safety, immunogenicity, and indicators of efficacy. Ann Intern Med, (82), 8168–8172.Google Scholar
  10. Duclos, P. (2003). Safety of immunization and adverse events following vaccination against hepatitis B. J Hepatol, (39), 83–88.CrossRefGoogle Scholar
  11. EUROHEP.NET (2004). Data on surveillance and prevention of hepatitis A and B in 22 countries, 1990–2001. Antwerp; (also available on http://www.eurohep.net)
  12. European Consensus Group on Hepatitis B immunity (2000). Are booster immunisations needed for lifelong hepatitis B immunity? Lancet, (355), 561–565.CrossRefGoogle Scholar
  13. Erhardt, A., Blondin, D., Hauck, K., Sagir, A., Kohnle, T., Heintges, T., & Häussinger, D. (2005). Response to interferon alfa is hepatitis B virus genotype dependent: genotype A is more sensitive to interferon than genotype D. Gut, (54), 1009–1013.PubMedCrossRefGoogle Scholar
  14. Francois, G., Hallauer, J., & Van Damme, P. (2002). Hepatitis B vaccination: how to reach risk groups. Vaccine, (21), 1–4.PubMedCrossRefGoogle Scholar
  15. Gaeta, G.B., Stroffolini, T., Chiaramonte, M., Ascione, T., Stornaiuolo, G., Lobello, S., Sagnelli, E. et al. (2000). Chronic hepatitis D: a vanishing disease? An Italian multicenter study. Hepatology, (32), 824–827.PubMedCrossRefGoogle Scholar
  16. Goldstein, S.T., Zhou, F., Hadler, S.C., Bell, B.P., Mast, E.E., & Margolis, H.S. (2005). A mathematical model to estimate global hepatitis B disease burden and vaccination impact. Int J Epidemiol, (34), 1329–1339. Available at: http://aim.path.org/en/vaccines/hepb/assessBurden/model/index.html (retrieved on 3 October 2008).PubMedCrossRefGoogle Scholar
  17. Hadler, S.C. & Margolis, H.S. (1992). Hepatitis B immunization: vaccine types, efficacy, and indications for immunization. In: Topics In Infectious Diseases. J.S. Remington, & M.N. Swartz (Eds.). (Vol. 12). Boston: Blackwell Scientific Publications, pp. 282–308.Google Scholar
  18. Hahné, S., Ramsay, M., Balogun, K., Edmunds, W.J., & Mortimer, P. (2004). Incidence and routes of transmission of hepatitis B virus in England and Wales, 1995–2000: implications for immunisation policy. J Clin Virol, (29), 211–220.PubMedCrossRefGoogle Scholar
  19. Hollinger, F.B. (1989). Factors influencing the immune response to hepatitis B vaccine, booster dose guidelines and vaccine protocol recommendations. Am J Med, 87(Suppl 3A), 36–40.CrossRefGoogle Scholar
  20. Jilg, W., Schmidt, M., Zachoval, R., & Deinhardt, F. (1984). Hepatitis B vaccination: how long does protection last? Lancet, (2), 458.PubMedCrossRefGoogle Scholar
  21. Jilg, W., Schmidt, M., & Deinhardt, F. (1988). Persistence of specific antibodies after hepatitis B vaccination. J Hepatol, (6), 201–207.PubMedCrossRefGoogle Scholar
  22. Kao, J.-H. & Chen, D.S. (2005). Hepatitis B vaccination: to boost or not to boost? Lancet, (366), 1337–1338.PubMedCrossRefGoogle Scholar
  23. Keating, G.M. & Noble, S. (2003). Recombinant hepatitis B vaccine (Engerix-B): a review of its immunogenicity and protective efficacy against hepatitis B. Drugs, (63), 1021–1051.PubMedCrossRefGoogle Scholar
  24. Kretzschmar, M. & de Wit, A. (2008). Universal hepatitis B vaccination. Lancet, (8), 85–87.CrossRefGoogle Scholar
  25. Lavanchy, D. (2004). Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat, (11), 97–107.PubMedCrossRefGoogle Scholar
  26. Lavanchy, D. (2005). Worldwide epidemiology of HBV infection, disease burden, and vaccine prevention. J Clin Virol, 34(Suppl 1), 1–3.CrossRefGoogle Scholar
  27. Lok, A.S.F. & McMahon, B.J. (2007). Chronic hepatitis B: AASLD practice guidelines. Hepatology, (45), 507–539.PubMedCrossRefGoogle Scholar
  28. Mahoney, F.J. (1999). Update on diagnosis, management and prevention of hepatitis B virus infection. Clin Microbiol Rev, (12), 351–366.PubMedGoogle Scholar
  29. Ng, K.P., Saw, T.L., Baki, A., Rozainah, K., Pang, K.W., & Ramanathan, M. (2005). Impact of expanded programme on immunization against hepatitis B infection in school children in Malaysia. Med Microbiol Immunol, (194), 163–168.PubMedCrossRefGoogle Scholar
  30. Niu, M.T. (1996). Review of 12 million doses shows hepatitis B vaccine safe. Vaccine Weekly, (4), 13–15.Google Scholar
  31. Perz, J.F., Elm, J.L., Jr., Fiore, A.E., Huggler, J.I., Kuhnert, W.L., & Effler, P.V. (2006). Near elimination of hepatitis B infections among Hawaii elementary school children universal infant hepatitis B vaccination. Pediatrics, (118), 1403–1408.PubMedCrossRefGoogle Scholar
  32. Piazza, M., Da Villa, G., Picciotto, L., Abrescia, N., Guadagnino, V., Memoli, A.M., Vegnente, A. et al. (1988). Mass vaccination against hepatitis B in infants in Italy. Lancet, (332), 1132.CrossRefGoogle Scholar
  33. Pollard, A.J. (2007). Hepatitis B vaccination. BMJ, (335), 950.PubMedCrossRefGoogle Scholar
  34. Rendi-Wagner, P., Shouval, D., Genton, B., Lurie, Y., Rumke, H., Boland, G., Cerny, A. et al. (2006). Comparative immunogenicity of a PreS/S hepatitis B vaccine in non- and low responders to conventional vaccine. Vaccine, (24), 2781–2789.PubMedCrossRefGoogle Scholar
  35. Romanò, L., Mele, A., Pariani, E., Zappa, A., & Zanetti, A. (2004). Update in the universal vaccination against hepatitis B in Italy: 12 years after its implementation. Eur J Public Health, 14(Suppl), S19.Google Scholar
  36. Safary, A. & André, F. (1999). Over a decade of experience with the yeast recombinant hepatitis B vaccine. Vaccine, (18), 57–67.CrossRefGoogle Scholar
  37. Shaefer, S. (2005). Hepatitis B virus: significance of genotypes. J Viral Hepat, (12), 111–124.CrossRefGoogle Scholar
  38. Shepard, E.W., Simard, E.P., Finelli, L., Fiore, A.E., & Bell, B.P. (2006). Hepatitis B virus infection: epidemiology and vaccination. Epidemiol Rev, (28), 112–125.PubMedCrossRefGoogle Scholar
  39. Sherlock, S. (1993). Clinical features of hepatitis. In: Viral Hepatitis. A.J. Zuckerman, H.S. Thomas (Eds.). London: Churchill Livingstone, pp. 1–11.Google Scholar
  40. Shouval, D., Ilan, Y., Adler, R., Deepen, R., Panet, A., Even-Chen, Z., Gorecki, M. et al. (1994). Improved immunogenicity in mice of a mammalian cell-derived recombinant hepatitis B vaccine containing pre-S1 and pre-S2 antigens as compared with conventional yeast-derived vaccines. Vaccine, (12), 1453–1459.PubMedCrossRefGoogle Scholar
  41. Szmuness, W., Stevens, C.E., Zang, E.A., Harley, E.J., & Kneller, A. (1981). A controlled clinical trial of the efficacy of the hepatitis B vaccine (Hepatavax B): a final report. Hepatology, (5), 377–385.Google Scholar
  42. Tan, J. & Lok, A.S.F. (2007). Update on viral hepatitis: 2006. Gastroenterology, (23), 263–267.Google Scholar
  43. Tandon, B.N. & Tandon, A. (1997). Epidemiological trends of viral hepatitis in Asia. In: Viral Hepatitis and Liver Disease. M. Rizzetto, R.H. Purcell, J.L. Gerin, & G. Verme (Eds.). Turin: Edizioni Minerva Medica, pp. 559–661.Google Scholar
  44. Tilson, L., Thornton, L., O’Flanagan, D., Johnson, H., & Barry, M. (2008). Cost-effectiveness of hepatitis B vaccination strategies in Ireland: an economic evaluation. Eur J Public Health, 18(3), 275–282.PubMedCrossRefGoogle Scholar
  45. Van Damme, P., Kane, M., & Meheus, A. (1997). Integration of hepatitis B vaccination into national immunisation programmes. BMJ, (314), 1033–1037.PubMedGoogle Scholar
  46. Van Damme, P., Van Herck, K., Leuridan, E., & Vorsters, A. (2004). Introducing universal hepatitis B vaccination in Europe: differences still remain between countries. Eurosurveillance Weekly, (9), 67–68.Google Scholar
  47. Van Damme, P. & Van Herck, K. (2007). A review of the long-term protection after hepatitis A and B vaccination. Travel Med Infect Dis, (5), 79–84.PubMedCrossRefGoogle Scholar
  48. van der Eijk, A.A., Niesters, H.G.M., Götz, H.M., Janssen, H.L.A., Schalm, S.W., Osterhaus, A.D.M.E., & de Man, R.A. (2004). Paired measurements of quantitative hepatitis B virus DNA in saliva and serum of chronic hepatitis B patients: implications for saliva as infectious agent. J Clin Virol, (29), 92–94.PubMedCrossRefGoogle Scholar
  49. van Houdt, R., Sonder, G.J., Dukers, N.H., Bovee, L.P., van den Hoek, A., Coutinho, R.A., & Bruisten, S.M. (2007). Impact of targeted hepatitis B vaccination program in Amsterdam, the Netherlands. Vaccine, (25), 2698–2705.PubMedCrossRefGoogle Scholar
  50. Venters, C., Graham, W., & Cassidy, W. (2004). Recombivax-HB: perspectives past, present and future. Expert Rev Vaccines, (3), 119–129.PubMedCrossRefGoogle Scholar
  51. Viviani, S., Jack, A., Hall, A.J., Maine, N., Mendy, M., Montesano, R., & Whittle, H.C. (1999). Hepatitis B vaccination in infancy in the Gambia: protection against carriage at 9 years of age. Vaccine, (17), 2946–2950.PubMedCrossRefGoogle Scholar
  52. Wainwright, R., Bulkow, L.R., Parkinson, A.J., Zanis, C., & McMahon, B.J. (1997). Protection provided by hepatitis B vaccine in a Yupik Eskimo Population: results of a 10 year study. J Infect Dis, (175), 674–677.PubMedGoogle Scholar
  53. West, D.J. & Calandra, G.B. (1996). Vaccine induced immunologic memory for hepatitis B surface antigen: implications for policy on booster vaccination. Vaccine, (14), 1019–1027.PubMedCrossRefGoogle Scholar
  54. Whittle, H.C., Maine, N., Pilkington, J., Mendy, M., Fortuin, M., Bunn, J., Allison, L. et al. (1995). Long-term efficacy of continuing hepatitis B vaccination in infancy in two Gambian villages. Lancet, (345), 1089–1092.PubMedCrossRefGoogle Scholar
  55. World Health Organization 1992. (1992). Informal consultation on quadrivalent diphtheria-tetanus-pertussis-hepatitis B vaccine. Final Report, pp.1–12, Geneva.Google Scholar
  56. World Health Organization (2004). Hepatitis B vaccines (WHO position paper). Weekly Epidemiol Record, (79), 255–263.Google Scholar
  57. World Health Organization 2006. Vaccines and biologicals. WHO vaccine preventable disease monitoring system. Global summary 2006 (data up to 2005). Available at http://www.who.int/vaccines-documents/GlobalSummary.pdf (retrieved on 15 September 2007).
  58. Zanetti, A.R., Tanzi, E., Romanò, L., & Grappasonni, I. (1993). Vaccination against hepatitis B: the Italian strategy. Vaccine, (11), 521–524.PubMedCrossRefGoogle Scholar
  59. Zanetti, A.R., Mariano, A., Romanò, L., D’Amelio, R., Chironna, M., Coppola, R.C., Cuccia, M., Mangione, R., Marrone, F., Negrone, F.S., Parlato, A., Zamparo, E., Zotti, C., Stroffolini, T., & Mele, A; Study Group. (2005). Long-term immunogenicity of hepatitis B vaccination and policy for booster: an Italian multicentre study. Lancet, 366(9494), 1379–1384.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  • Pierre Van Damme
    • 1
  • Alessandro R. Zanetti
    • 2
  • Daniel Shouval
    • 3
  • Koen Van Herck
    • 1
    • 4
  1. 1.Faculty of Medicine, Centre for the Evaluation of VaccinationVaccine & Infectious Disease Institute, University of AntwerpAntwerpBelgium
  2. 2.Faculty of Medicine, Department of Public Health-Microbiology-VirologyUniversity of MilanMilanItaly
  3. 3.Department of MedicineLiver Unit, Hadassah-Hebrew University Hospital JerusalemJerusalemIsrael
  4. 4.4Research Foundation – Flanders (FWO)BrusselsBelgium

Personalised recommendations